Home Companies Catalysts Deep Dives
Imjudo tremelimumab APPROVED
Drug Profile
ModalityAntibody
RouteIV
Therapy AreaOncology
Launch2022-10-21
US LOE2033-10-01
Peak Sales Est$1500M
Formulations[{"id":"imjudo-iv","doses":"300mg","route":"IV","setting":"INFUSION_CENTER","frequency":"Single dose
Companies
AZN (ORIGINATOR)100%
Mechanism: CTLA-4 inhibitor
Expert: Human IgG2 monoclonal antibody targeting CTLA-4, enhancing T-cell activation and proliferation in the priming phase of immune response.
Everyday: Activates the immune system to fight cancer by removing a brake on immune cells.
Targets: ["CTLA-4"]
Revenue History
PeriodRevenue ($M)
2023$476M
2024$812M
Q1 2025$250M
Programs (2)
IndicationStageKey StudyRegional Status
HCCAPPROVEDHIMALAYA[{"stage":"APPROVED","region":"US","approval_date":"2022-10-21"},{"stage":"APPRO
mNSCLCAPPROVEDPOSEIDON[{"stage":"APPROVED","region":"US","approval_date":"2022-11-10"}]
Notes
CTLA-4 antibody. Used with Imfinzi.
Data from Supabase · Updated 2026-03-24